StockData

Artiva Biotherapeutics vs Cardiff Oncology

ARTV and CRDF side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ARTV and CRDF compare

Artiva Biotherapeutics is the larger company, worth 2.9 times as much as Cardiff Oncology ($189M against $65.8M).

Artiva Biotherapeutics scores higher on the StockData Score (8 against 7 for Cardiff Oncology), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricARTVCRDF
Size and price
Market cap$189M$65.8M
Share price$3.86$0.846
Change, 1 year18.8%−60.3%
Change, 5 years–−84.9%
Beta (5Y)4.842.50
Employees10431
StockData Score
Total score8 (better)7
Valuation score1 (better)0
Growth score01 (better)
Performance score11
Health score6 (better)5
Dividend score00
Valuation
P/S–130×
P/B0.5× (better)2.5×
FCF yield−40.8%–
Growth
Revenue growth (TTM)–−7.0%
Revenue growth, 5Y average–10.1%
Profitability
Operating margin–−8320%
Net margin–−7884%
Return on equity−36.6% (better)−94.1%
Return on invested capital−3203%–
Financial health
Debt / equity0.000.00
Current ratio24.16 (better)3.30
Altman Z-score4.16 (better)−16.20
Piotroski F-score11
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions83.2%24.2%
Held by insiders68.3%4.9%
Insider net buying, 12 months$106M (better)$1.1M
Superinvestors holding1–
Short interest, % of float19.0%16.6%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.